About Jennerex
Jennerex, Inc. is a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. Our lead product JX-594 is currently in two mid-stage clinical trials in patients with liver cancer: 1) an international, randomized, Phase 2 dose-response trial, and 2) a Phase 2 study in combination with sorafenib. Published studies designed to establish optimal dosing and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types, with longer term survival and an excellent safety profile.
JX-594, JX-929 and other product candidates under development are designed to attack cancer tumors through three synergistic and complementary mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction and 3) the stimulation of the body's immune response against cancer cells.
We are headquartered in San Francisco and have research and development operations in Ottawa, Canada (OHRI labs) and Pusan, South Korea (SillaJen labs).
